Eucafluff Expands Businesses in Europe, Asia, and in the United States
11.4.2019 09:00:00 EEST | Business Wire | Press release
Suzano (NYSE:SUZ), a merger between Suzano Papel e Celulose and Fibria, has increased Eucafluff sales in the European, Asian, and US markets. The product is the only eucalyptus-based fluff pulp sold in the world and is used in personal hygiene items such as diapers and sanitary napkins. Eucafluff is considered a reference of innovation and sustainability and, therefore, has been approved by major global manufacturers. In the last 6 months, companies such as Ontex and Vinda International, amongst other local players in Europe, the United States, Japan, and China have been buying from Suzano.
Currently, 86% of Eucafluff's sales are made overseas, in which 25% are sold in Europe. "The acceptance of our fluff pulp in mature markets and multinational companies has confirmed the good performance that eucalyptus fiber can also bring to the hygiene market. We are committed to improving the quality and performance of our client’s end products and this has reflected in the global partnerships we have achieved these past months, " says Alexandre Corrêa, Executive Manager of the Business Unit at Suzano.
Developed by Suzano and resulting from 11 years of research, Eucafluff is the first bleached kraft pulp of eucalyptus fluff type in the world, and is be applied in absorbent products as well as personal hygiene products, disposables like children and adults diapers, sanitary napkins for women, amongst other applications. The key benefits provided by this unique fiber are a higher liquid absorption and retention at product cores and greater comfort and discretion to the end user, such as in the case of application in incontinence pants. These benefits are due to the greater compressibility of the eucalyptus fiber, a feature that has also brought other associated benefits as reduction in packaging size, transportation, and storage costs.
Suzano has 95 years of history and 11 factories, and is present in the lives of more than 2 billion people through its products. The company is the world´s leader in the production of eucalyptus pulp, a raw material developed by the company in the 1960s, is also a world pioneer in the production of eucalyptus fluff and is one of the largest paper manufacturers in Latin America. Since its inception, it has invested in innovative and unique solutions, seeking the substitution of raw materials of fossil origin for other sources of renewable origin.
About Suzano
Suzano , the company resulting from the merger of Suzano Pulp & Paper and Fibria, is committed to being a global reference in the sustainable use of natural resources. The world's leading producer of eucalyptus pulp and one of Latin America’s largest paper producers, Suzano exports to more than 80 countries and, through its products, plays a part in the lives of over two billion people. With ten mills and the joint operation Veracel, Suzano has annual installed capacity of 11 million tons of market pulp and 1.4 million tons of paper. Suzano has approximately 37,000 direct and indirect employees and for over 90 years has invested in innovative solutions based on eucalyptus cultivation that enable it to substitute the use of fossil-based materials with renewable bio-based materials. The company adopts the highest standards of corporate governance on the exchanges where its stock is traded, namely the B3 in Brazil and the NYSE in the United States.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190410005839/en/
Contact information
PLANIN – Suzano’s PR Agency
Angélica Consiglio, Beatriz
Imenes and team – www.planin.com
E-mail:
suzano@planin.com - Phone: +55
(11) 2138-8940
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
